Fox Run Management L.L.C. Buys 24,391 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Fox Run Management L.L.C. grew its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 214.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,743 shares of the company’s stock after purchasing an additional 24,391 shares during the period. Fox Run Management L.L.C.’s holdings in Kiniksa Pharmaceuticals International were worth $989,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in Kiniksa Pharmaceuticals International by 4.7% in the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after buying an additional 151,604 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after acquiring an additional 651,700 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Nuveen LLC bought a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $16,992,000. Finally, AQR Capital Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 149.1% during the 1st quarter. AQR Capital Management LLC now owns 491,761 shares of the company’s stock valued at $10,922,000 after purchasing an additional 294,319 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Down 0.7%

Shares of NASDAQ KNSA opened at $38.37 on Friday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $42.05. The firm’s 50-day moving average is $37.41 and its 200-day moving average is $31.77. The firm has a market capitalization of $2.84 billion, a PE ratio of 85.27 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business had revenue of $180.85 million during the quarter, compared to analyst estimates of $166.64 million. During the same quarter in the prior year, the company earned ($0.18) earnings per share. The company’s quarterly revenue was up 61.2% on a year-over-year basis. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on KNSA shares. Wedbush reissued an “outperform” rating and issued a $48.00 price objective (up previously from $44.00) on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, October 28th. Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. Citigroup increased their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Finally, Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

Insiders Place Their Bets

In related news, insider Ross Moat sold 3,523 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total value of $124,397.13. Following the sale, the insider directly owned 9,415 shares in the company, valued at $332,443.65. This trade represents a 27.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Michael R. Megna sold 50,490 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the transaction, the chief accounting officer directly owned 27,046 shares in the company, valued at $1,051,278.02. The trade was a 65.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 784,112 shares of company stock valued at $28,685,561 in the last ninety days. 53.48% of the stock is currently owned by insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.